Regenxbio RGNX
NASDAQ RGNX
$8.94 -0.26 (-2.83%)
As of: Sep 4, 2026 · 3:59 PM EDT

Regenxbio (RGNX) Total Debt (2014)

Regenxbio (RGNX) posted quarterly Total Debt of $1.4 million for Q4 2014.

Analysis

Regenxbio (RGNX) Total Debt (2014) Analysis & Trends

Regenxbio's Total Debt history runs 1 years deep, the most recent figure standing at $1.4 million for Q4 2014.

  • In Q4 2014, Total Debt changed N/A year-over-year to $1.4 million; the TTM figure through Dec 2014 stood at $1.4 million (changed N/A YoY), while the FY2014 annual figure was $1.4 million, changed N/A from the prior year.
  • Total Debt for Q4 2014 stood at $1.4 million.
  • The five-year high for Total Debt was $1.4 million in Q4 2014, with the low at $1.4 million in Q4 2014.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 1.99 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 591.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1.07 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - 9.34 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 546.77 Mn
10 Regenxbio 472.74 Mn 367.22 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2014 2.40 Mn